James Flynn Biography and Net Worth

Director of Larimar Therapeutics

James Flynn is the Director of Larimar Therapeutics.

What is James E. Flynn's net worth?: The estimated net worth of James E. Flynn is at least $32.49 million as of November 11th, 2024. Flynn owns 5,274,735 shares of Larimar Therapeutics stock worth more than $32,492,368 as of November 23rd. This net worth evaluation does not reflect any other assets that Flynn may own. Learn More about James E. Flynn's net worth.
How do I contact James E. Flynn?: The corporate mailing address for Flynn and other Larimar Therapeutics executives is THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD PA, 19004. Larimar Therapeutics can also be reached via phone at (844) 511-9056 and via email at [email protected]. Learn More on James E. Flynn's contact information.
Has James E. Flynn been buying or selling shares of Larimar Therapeutics?: James E. Flynn has not been actively trading shares of Larimar Therapeutics over the course of the past ninety days. Most recently, on Friday, February 16th, James E. Flynn bought 4,290,617 shares of Larimar Therapeutics stock. The stock was acquired at an average cost of $8.74 per share, with a total value of $37,499,992.58. Following the completion of the transaction, the director now directly owns 6,151,406 shares of the company's stock, valued at $53,763,288.44. Learn More on James E. Flynn's trading history.
Are insiders buying or selling shares of Larimar Therapeutics?: In the last twelve months, Larimar Therapeutics insiders bought shares 2 times. They purchased a total of 4,292,617 shares worth more than $37,521,992.58. The most recent insider tranaction occured on February, 16th when Director James E Flynn bought 4,290,617 shares worth more than $37,499,992.58. Insiders at Larimar Therapeutics own 3.5% of the company. Learn More about insider trades at Larimar Therapeutics.
Information on this page was last updated on 2/16/2024.

James E. Flynn Insider Trading History at Larimar Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/16/2024	Buy	4,290,617	$8.74	$37,499,992.58	6,151,406
6/30/2021	Buy	685,710	$8.75	$5,999,962.50

James E. Flynn Buying and Selling Activity at Larimar Therapeutics

Larimar Therapeutics Company Overview

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Today's Range

Now: $6.16

$6.04

$6.34

50 Day Range

MA: $7.25

$6.08

$9.29

2 Week Range

Now: $6.16

$3.19

$13.68

Volume

402,091 shs

Average Volume

765,931 shs

Market Capitalization

$393.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

From Porter & Company | Ad

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.